Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2017

View Archived Issues

GW Pharmaceuticals reacquires full rights to Sativex in the U.S.

Flexion acquires rights to nonopioid, intra-articular therapeutic for osteoarthritis of the knee

New model reveals flunarizine effects in alternating hemiplegia of childhood

Axsome Therapeutics and Duke University to collaborate on phase II study of AXS-05

Telix and Memorial Sloan Kettering collaborate on TLX-250 to image clear cell RCC

Synairgen and Pharmaxis revise LOXL2 collaboration agreement

First in vivo results for LSD1 inhibitor show promise for the treatment of SCD

Asklepios announces formation of new portfolio company Actus Therapeutics

Mesoblast grants TiGenix access to patents to support commercialization of Cx-601 for fistulae

Corbus Pharmaceuticals initiates phase III RESOLVE-1 trial testing anabasum

Amicus Therapeutics applies for U.S. approval of migalastat for Fabry disease

Dimerix and Proteomics partner to evaluate companion diagnostic for DMX-200

Cellectar Biosciences submits IND in U.S. for phase I pediatric study of CLR-131

Novel anti-CD47 MAbs presented at San Antonio Breast Cancer Symposium

Akcea begins phase II trial of AKCEA-ANGPTL3-LRx

FDA approves Xeljanz and Xeljanz XR for psoriatic arthritis

Trovagene submits protocol for phase II study of PCM-075 to FDA

FDA clears Jenrin's IND for CB1 receptor inverse agonist

Phase III trial for PF-04965842 in atopic dermatitis begins

Phase IIb study of bimekizumab in ankylosing spondylitis meets primary objective

FDA grants fast track designation to WTX-101 for Wilson's disease

FDA agrees to Consensi as brand name for Kitov's KIT-302

pSivida announces phase I data on sustained-release implant for osteoarthritis of the knee

Roche patents xanthone derivatives for HBV

Protagonist Therapeutics reports topline results from PTG-300 phase I study

SIMM presents novel FGFR inhibitors

FDA awards fast track designation to Renova's gene transfer product

Novel P2RX2/P2RX3 antagonists presented by Shionogi

Merck KGaA presents new ATR kinase inhibitors

Preclinical synergy seen with BR-101801 plus venetoclax in double hit and double expressor DLBCL

Novel PROTAC compounds presented by KRICT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...